New Delhi: Serum Institute of India (SII) on Wednesday announced that it will charge state governments Rs 400 and private hospitals Rs 600 per dose of its Covishield COVID-19 vaccine, finally answering the question of how the company expects to price the product it manufactures and accelerate India’s vaccination drive.
The Serum Institute produces Covishield, the COVID-19 vaccine developed by Oxford University and AstraZeneca. Covishield is among the three COVID-19 vaccines authorised for emergency use in India.
The company said 50 percent of its capacities will serve the government of India’s vaccination programme, and the remaining 50 percent capacity will be for state governments and private hospitals.
“For the next two months, we will address the limited capacity by scaling up the vaccine production,” it said in a statement.